Moscow Clinical scientific Center
Moscow, Entuziastov Shosse,86, 111123, Russia
NCT Number: NCT03208192
Background: until now, there is no agreement about the safest and feasible method for liver parenchyma transection during laparoscopic liver resection.
Study design: prospective, randomized, single-center The purpose of the study: comparison of short-term results of two methods of parenchyma liver transection during laparoscopic liver resection
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Moscow, Entuziastov Shosse,86, 111123, Russia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
liver transection during laparoscopic liver resection
Time frame: 1 day
Absolute blood loss (ml) will be calculated as the amount of blood (collected only during the parenchyma resection) in suction the container after the subtraction of all irrigating fluids and weighing operative sponges.
Time frame: 1 day
Аbsolute measurement of blood loss in relation to resection size (ml/cm^2).
Time frame: 1 day
Duration of liver parenchyma transaction (min)
Time frame: 1 day
the number of participants who needed to apply the Pringle maneuver
Time frame: 1 day
The total duration of Pringle maneuver (min)
Time frame: up to 1 month
Hospital stay (day)
Time frame: 30 days
Morbidity according to Clavien-Dindo classification (it is advisable to activate complications class II-V). The Clavien-Dindo classification (CDC) is a standardized system for the registration of surgical complications. It consists of 7 grades (I, II, IIIa, IIIb, IVa, IVb and V). The major characteristic of the CDC system is that the severity of a complication is graded based on the type of therapy required to treat the complication. The CDC system has been validated and accepted worldwide for use in many fields of surgery. The complications that change the treatment of grade II-V.
Moscow Clinical Scientific Center
Other
Acronym: LLS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04892810
Adenocarcinoma, Carcinoma
Grenoble, France
View Trial DetailsNCT04930315
Adenocarcinoma, Carcinoma
Hangzhou, Zhejiang, China
View Trial DetailsNCT05128032
Adenocarcinoma, Carcinoma
Boston, Massachusetts, United States
View Trial DetailsNCT04374877
Adenocarcinoma, Advanced Solid Tumor
Duarte, California, United States
View Trial Details